Role of molecular markers in the diagnosis and therapy of renal cell carcinoma.

[1]  S. Fuhrman,et al.  Prognostic significance of morphologic parameters in renal cell carcinoma , 1982, The American journal of surgical pathology.

[2]  D. Ruiter,et al.  Monoclonal antibody G 250 recognizes a determinant present in renal‐cell carcinoma and absent from normal kidney , 1986, International journal of cancer.

[3]  N. Bander,et al.  Antibody localization in human renal cell carcinoma: a phase I study of monoclonal antibody G250. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  R. Kettmann,et al.  Human MN/CA9 gene, a novel member of the carbonic anhydrase family: structure and exon to protein domain relationships. , 1996, Genomics.

[5]  E. Stanbridge,et al.  Identification of the MN/CA9 protein as a reliable diagnostic biomarker of clear cell carcinoma of the kidney. , 1997, Cancer research.

[6]  S. Larson,et al.  Phase I/II radioimmunotherapy trial with iodine-131-labeled monoclonal antibody G250 in metastatic renal cell carcinoma. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[7]  C. Wykoff,et al.  The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis , 1999, Nature.

[8]  S. Saga,et al.  MN/CA IX/G250 as a potential target for immunotherapy of renal cell carcinomas , 1999, British Journal of Cancer.

[9]  M Mazumdar,et al.  Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  J L Warren,et al.  Rising incidence of renal cell cancer in the United States. , 1999, JAMA.

[11]  R. Brakenhoff,et al.  Molecular cloning and immunogenicity of renal cell carcinoma‐associated antigen G250 , 2000, International journal of cancer.

[12]  M. Ivan,et al.  Ubiquitination of hypoxia-inducible factor requires direct binding to the β-domain of the von Hippel–Lindau protein , 2000, Nature Cell Biology.

[13]  M. Kattan,et al.  A postoperative prognostic nomogram for renal cell carcinoma. , 2001, The Journal of urology.

[14]  K. Furge,et al.  Gene expression profiling of clear cell renal cell carcinoma: Gene identification and prognostic classification , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[15]  R. Figlin,et al.  Validation of the ucla integrated staging system for patients with renal cell carcinoma. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  W. Sly,et al.  Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer. , 2001, The American journal of pathology.

[17]  R. Figlin,et al.  Improved prognostication of renal cell carcinoma using an integrated staging system. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Adrian L. Harris,et al.  Hypoxia — a key regulatory factor in tumour growth , 2002, Nature Reviews Cancer.

[19]  J. Cheville,et al.  An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. , 2002, The Journal of urology.

[20]  C. Niederberger,et al.  What nonresponse to intracavernous injection really indicates: a determination by quantitative analysis. , 2002, The Journal of urology.

[21]  G. Semenza,et al.  HIF-1 and tumor progression: pathophysiology and therapeutics. , 2002, Trends in molecular medicine.

[22]  R. Figlin,et al.  Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  Steve Horvath,et al.  Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[24]  S. Horvath,et al.  Carbonic Anhydrase IX Is an Independent Predictor of Survival in Advanced Renal Clear Cell Carcinoma , 2003 .

[25]  Joanna H Shih,et al.  Predicting survival in patients with metastatic kidney cancer by gene-expression profiling in the primary tumor , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[26]  Seth M Steinberg,et al.  A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. , 2003, The New England journal of medicine.

[27]  R. Figlin,et al.  Validation of an integrated staging system toward improved prognostication of patients with localized renal cell carcinoma in an international population. , 2003, The Journal of urology.

[28]  S. Horvath,et al.  1651: Molecular Prognostic Modeling Using Protein Expression Profile in Clear Cell Renal Carcinoma , 2004 .

[29]  J. Patard,et al.  Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: an international multicenter study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  L. Schmidt,et al.  Searching for the hereditary causes of renal-cell carcinoma , 2004, Nature Reviews Cancer.

[31]  C. Lamers,et al.  A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients , 2004, British Journal of Cancer.

[32]  J. Lam,et al.  Advances in immune-based therapies of renal cell carcinoma , 2004, Expert review of anticancer therapy.

[33]  Ximing J. Yang,et al.  Gene Expression Profiling of Renal Cell Carcinoma , 2004, Clinical Cancer Research.

[34]  S. Signoretti,et al.  Carbonic Anhydrase IX (CAIX) expression predicts for renal cell cancer (RCC) patient response and survival to IL-2 therapy. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  J. Lam,et al.  Tissue Array-Based Predictions of Pathobiology, Prognosis, and Response to Treatment for Renal Cell Carcinoma Therapy , 2004, Clinical Cancer Research.

[36]  S. Horvath,et al.  Using tumor markers to predict the survival of patients with metastatic renal cell carcinoma. , 2005, The Journal of urology.

[37]  J. Leppert,et al.  Characterization of the mTOR pathway in renal cell carcinoma and its use in predicting patient selection for agents targeting this pathway , 2005 .

[38]  Lee M Ellis,et al.  Expression and function of vascular endothelial growth factor receptor-1 on human colorectal cancer cells , 2005, Oncogene.

[39]  J. Lam,et al.  Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy. , 2005, The Journal of urology.

[40]  Targeting the vascular endothelial growth factor pathway in renal cell carcinoma: A tissue array based analysis , 2005 .

[41]  A. Jemal,et al.  Cancer Statistics, 2005 , 2005, CA: a cancer journal for clinicians.

[42]  J. Lam,et al.  Surveillance following radical or partial nephrectomy for renal cell carcinoma , 2005, Current urology reports.

[43]  350: Characterization of the MTOR Pathway in Renal Cell Carcinoma and its Use in Predicting Patient Selection for Agents Targeting this Pathway , 2005 .

[44]  T. Mekhail,et al.  Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  Expression of the vascular endothelial growth factor family in tumor dissemination and disease free survival in clear cell renal cell carcinoma , 2005 .